March 16, 2017 / 11:28 PM / 6 months ago

BRIEF-Fate Therapeutics qtrly net loss per common share $ 0.21

March 16 (Reuters) - Fate Therapeutics Inc

* Fate Therapeutics reports fourth quarter 2016 financial results

* Q4 revenue $1.0 million versus I/B/E/S view $958,000

* Qtrly net loss per common share $ 0.21

* Fate Therapeutics Inc - cash, cash equivalents and short-term investments as of dec 31, 2016 were $92.1 million compared to $64.8 million as of dec 31, 2015

* Q4 earnings per share view $-0.29, revenue view $957500.00 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below